The World Market for Glycosides, Glands or Other Organs and Extracts, Antisera, Vaccines, and Similar Products: A 2024 Global Trade Perspective
This report was created for strategic planners, international executives, and import/export managers who are concerned with the market for glycosides, glands or other organs and extracts, antisera, vaccines, and similar products. With the globalization of this market, managers can no longer be contented with a local view. Nor can managers be contented with out-of-date statistics that appear several years after the fact. Professor Philip M. Parker, the Chair Professor of Management Science at INSEAD, has developed a methodology, based on macroeconomic and trade models, to estimate the market for glycosides, glands or other organs and extracts, antisera, vaccines, and similar products for those countries serving the world market via exports or supplying from various countries via imports. He does so for the current year based on a variety of key historical indicators and econometric models.
"Glycosides, glands or other organs and extracts, antisera, vaccines, and similar products" as a category is defined in this report following the definition given by the United Nations Statistics Division Classification Registry using the Standard International Trade Classification, Revision 3 (SITC, Rev. 3). The SITC code that defines "glycosides, glands or other organs and extracts, antisera, vaccines, and similar products" is 5416.
- 1 METHODOLOGY
- 1.1 OUR APPROACH
- 2 THE WORLD MARKET
- 2.1 EXPORTS
- 2.1.1 THE WORLD MARKET: GLYCOSIDES, GLANDS OR OTHER ORGANS AND EXTRACTS, ANTISERA, VACCINES, AND SIMILAR PRODUCTS EXPORT SUPPLIES IN 2024
- 2.2 IMPORTS
- 2.2.1 THE WORLD MARKET: IMPORTED GLYCOSIDES, GLANDS OR OTHER ORGANS AND EXTRACTS, ANTISERA, VACCINES, AND SIMILAR PRODUCTS IN 2024
- 3 EXPORTS
- 3.1 AFRICA: EXPORT SUPPLIES OF GLYCOSIDES, GLANDS OR OTHER ORGANS AND EXTRACTS, ANTISERA, VACCINES, AND SIMILAR PRODUCTS IN 2024
- 3.1.1 EXECUTIVE SUMMARY
- 3.1.2 BOTSWANA
- 3.1.3 CAMEROON
- 3.1.4 EGYPT
- 3.1.5 ESWATINI
- 3.1.6 ETHIOPIA
- 3.1.7 KENYA
- 3.1.8 MALI
- 3.1.9 MAURITIUS
- 3.1.10 MOROCCO
- 3.1.11 NAMIBIA
- 3.1.12 NIGERIA
- 3.1.13 RWANDA
- 3.1.14 SENEGAL
- 3.1.15 SIERRA LEONE
- 3.1.16 SOUTH AFRICA
- 3.1.17 TANZANIA
- 3.1.18 THE CENTRAL AFRICAN REPUBLIC
- 3.1.19 TUNISIA
- 3.1.20 UGANDA
- 3.1.21 ZIMBABWE
- 3.2 ASIA: EXPORT SUPPLIES OF GLYCOSIDES, GLANDS OR OTHER ORGANS AND EXTRACTS, ANTISERA, VACCINES, AND SIMILAR PRODUCTS IN 2024
- 3.2.1 EXECUTIVE SUMMARY
- 3.2.2 BANGLADESH
- 3.2.3 CHINA
- 3.2.4 HONG KONG
- 3.2.5 INDIA
- 3.2.6 INDONESIA
- 3.2.7 JAPAN
- 3.2.8 MACAU
- 3.2.9 MALAYSIA
- 3.2.10 NEPAL
- 3.2.11 NORTH KOREA
- 3.2.12 SINGAPORE
- 3.2.13 SOUTH KOREA
- 3.2.14 SRI LANKA
- 3.2.15 TAIWAN
- 3.2.16 THAILAND
- 3.2.17 THE PHILIPPINES
- 3.2.18 VIETNAM
- 3.3 EUROPE: EXPORT SUPPLIES OF GLYCOSIDES, GLANDS OR OTHER ORGANS AND EXTRACTS, ANTISERA, VACCINES, AND SIMILAR PRODUCTS IN 2024
- 3.3.1 EXECUTIVE SUMMARY
- 3.3.2 ALBANIA
- 3.3.3 AUSTRIA
- 3.3.4 BELARUS
- 3.3.5 BELGIUM
- 3.3.6 BOSNIA AND HERZEGOVINA
- 3.3.7 BULGARIA
- 3.3.8 CROATIA
- 3.3.9 CYPRUS
- 3.3.10 DENMARK
- 3.3.11 ESTONIA
- 3.3.12 FINLAND
- 3.3.13 FRANCE
- 3.3.14 GEORGIA
- 3.3.15 GERMANY
- 3.3.16 GREECE
- 3.3.17 HUNGARY
- 3.3.18 ICELAND
- 3.3.19 IRELAND
- 3.3.20 ITALY
- 3.3.21 KAZAKHSTAN
- 3.3.22 LATVIA
- 3.3.23 LITHUANIA
- 3.3.24 LUXEMBOURG
- 3.3.25 MACEDONIA
- 3.3.26 MALTA
- 3.3.27 NORWAY
- 3.3.28 POLAND
- 3.3.29 PORTUGAL
- 3.3.30 ROMANIA
- 3.3.31 RUSSIA
- 3.3.32 SLOVAKIA
- 3.3.33 SLOVENIA
- 3.3.34 SPAIN
- 3.3.35 SWEDEN
- 3.3.36 SWITZERLAND
- 3.3.37 THE CZECH REPUBLIC
- 3.3.38 THE NETHERLANDS
- 3.3.39 THE UNITED KINGDOM
- 3.3.40 UKRAINE
- 3.4 LATIN AMERICA: EXPORT SUPPLIES OF GLYCOSIDES, GLANDS OR OTHER ORGANS AND EXTRACTS, ANTISERA, VACCINES, AND SIMILAR PRODUCTS IN 2024
- 3.4.1 EXECUTIVE SUMMARY
- 3.4.2 ARGENTINA
- 3.4.3 BRAZIL
- 3.4.4 CHILE
- 3.4.5 COLOMBIA
- 3.4.6 COSTA RICA
- 3.4.7 ECUADOR
- 3.4.8 EL SALVADOR
- 3.4.9 GUATEMALA
- 3.4.10 HONDURAS
- 3.4.11 MEXICO
- 3.4.12 NICARAGUA
- 3.4.13 PANAMA
- 3.4.14 PARAGUAY
- 3.4.15 PERU
- 3.4.16 URUGUAY
- 3.4.17 VENEZUELA
- 3.5 NORTH AMERICA & THE CARIBBEAN: EXPORT SUPPLIES OF GLYCOSIDES, GLANDS OR OTHER ORGANS AND EXTRACTS, ANTISERA, VACCINES, AND SIMILAR PRODUCTS IN 2024
- 3.5.1 EXECUTIVE SUMMARY
- 3.5.2 BERMUDA
- 3.5.3 CANADA
- 3.5.4 CUBA
- 3.5.5 GREENLAND
- 3.5.6 ST. KITTS AND NEVIS
- 3.5.7 THE DOMINICAN REPUBLIC
- 3.5.8 THE UNITED STATES
- 3.5.9 TRINIDAD AND TOBAGO
- 3.6 OCEANIA: EXPORT SUPPLIES OF GLYCOSIDES, GLANDS OR OTHER ORGANS AND EXTRACTS, ANTISERA, VACCINES, AND SIMILAR PRODUCTS IN 2024
- 3.6.1 EXECUTIVE SUMMARY
- 3.6.2 AUSTRALIA
- 3.6.3 FIJI
- 3.6.4 NEW CALEDONIA
- 3.6.5 NEW ZEALAND
- 3.7 THE MIDDLE EAST: EXPORT SUPPLIES OF GLYCOSIDES, GLANDS OR OTHER ORGANS AND EXTRACTS, ANTISERA, VACCINES, AND SIMILAR PRODUCTS IN 2024
- 3.7.1 EXECUTIVE SUMMARY
- 3.7.2 AFGHANISTAN
- 3.7.3 ARMENIA
- 3.7.4 AZERBAIJAN
- 3.7.5 BAHRAIN
- 3.7.6 IRAN
- 3.7.7 IRAQ
- 3.7.8 ISRAEL
- 3.7.9 JORDAN
- 3.7.10 LEBANON
- 3.7.11 PAKISTAN
- 3.7.12 SAUDI ARABIA
- 3.7.13 SYRIA
- 3.7.14 TAJIKISTAN
- 3.7.15 THE UNITED ARAB EMIRATES
- 3.7.16 TURKEY
- 3.7.17 UZBEKISTAN
- 4 IMPORTS
- 4.1 AFRICA: GLYCOSIDES, GLANDS OR OTHER ORGANS AND EXTRACTS, ANTISERA, VACCINES, AND SIMILAR PRODUCTS IMPORTS IN 2024
- 4.1.1 EXECUTIVE SUMMARY
- 4.1.2 ALGERIA
- 4.1.3 BENIN
- 4.1.4 BOTSWANA
- 4.1.5 BURKINA FASO
- 4.1.6 BURUNDI
- 4.1.7 CAMEROON
- 4.1.8 CAPE VERDE
- 4.1.9 COTE D'IVOIRE
- 4.1.10 EGYPT
- 4.1.11 ETHIOPIA
- 4.1.12 GUINEA
- 4.1.13 MADAGASCAR
- 4.1.14 MALAWI
- 4.1.15 MAURITANIA
- 4.1.16 MAURITIUS
- 4.1.17 MOROCCO
- 4.1.18 MOZAMBIQUE
- 4.1.19 NAMIBIA
- 4.1.20 NIGER
- 4.1.21 NIGERIA
- 4.1.22 RWANDA
- 4.1.23 SAO TOME E PRINCIPE
- 4.1.24 SENEGAL
- 4.1.25 SOUTH AFRICA
- 4.1.26 TANZANIA
- 4.1.27 THE CENTRAL AFRICAN REPUBLIC
- 4.1.28 THE DEMOCRATIC REPUBLIC OF THE CONGO
- 4.1.29 UGANDA
- 4.1.30 ZAMBIA
- 4.1.31 ZIMBABWE
- 4.2 ASIA: GLYCOSIDES, GLANDS OR OTHER ORGANS AND EXTRACTS, ANTISERA, VACCINES, AND SIMILAR PRODUCTS IMPORTS IN 2024
- 4.2.1 EXECUTIVE SUMMARY
- 4.2.2 BRUNEI
- 4.2.3 CHINA
- 4.2.4 HONG KONG
- 4.2.5 INDIA
- 4.2.6 INDONESIA
- 4.2.7 JAPAN
- 4.2.8 MACAU
- 4.2.9 MALAYSIA
- 4.2.10 MONGOLIA
- 4.2.11 NEPAL
- 4.2.12 SINGAPORE
- 4.2.13 SOUTH KOREA
- 4.2.14 SRI LANKA
- 4.2.15 TAIWAN
- 4.2.16 THAILAND
- 4.2.17 THE MALDIVES
- 4.2.18 THE PHILIPPINES
- 4.2.19 VIETNAM
- 4.3 EUROPE: GLYCOSIDES, GLANDS OR OTHER ORGANS AND EXTRACTS, ANTISERA, VACCINES, AND SIMILAR PRODUCTS IMPORTS IN 2024
- 4.3.1 EXECUTIVE SUMMARY
- 4.3.2 ALBANIA
- 4.3.3 ANDORRA
- 4.3.4 AUSTRIA
- 4.3.5 BELARUS
- 4.3.6 BELGIUM
- 4.3.7 BOSNIA AND HERZEGOVINA
- 4.3.8 BULGARIA
- 4.3.9 CROATIA
- 4.3.10 CYPRUS
- 4.3.11 DENMARK
- 4.3.12 ESTONIA
- 4.3.13 FINLAND
- 4.3.14 FRANCE
- 4.3.15 GEORGIA
- 4.3.16 GERMANY
- 4.3.17 GREECE
- 4.3.18 HUNGARY
- 4.3.19 ICELAND
- 4.3.20 IRELAND
- 4.3.21 ITALY
- 4.3.22 KAZAKHSTAN
- 4.3.23 LATVIA
- 4.3.24 LITHUANIA
- 4.3.25 LUXEMBOURG
- 4.3.26 MACEDONIA
- 4.3.27 MALTA
- 4.3.28 MOLDOVA
- 4.3.29 NORWAY
- 4.3.30 POLAND
- 4.3.31 PORTUGAL
- 4.3.32 ROMANIA
- 4.3.33 RUSSIA
- 4.3.34 SLOVAKIA
- 4.3.35 SLOVENIA
- 4.3.36 SPAIN
- 4.3.37 SWEDEN
- 4.3.38 SWITZERLAND
- 4.3.39 THE CZECH REPUBLIC
- 4.3.40 THE NETHERLANDS
- 4.3.41 THE UNITED KINGDOM
- 4.3.42 UKRAINE
- 4.4 LATIN AMERICA: GLYCOSIDES, GLANDS OR OTHER ORGANS AND EXTRACTS, ANTISERA, VACCINES, AND SIMILAR PRODUCTS IMPORTS IN 2024
- 4.4.1 EXECUTIVE SUMMARY
- 4.4.2 ARGENTINA
- 4.4.3 BELIZE
- 4.4.4 BOLIVIA
- 4.4.5 BRAZIL
- 4.4.6 CHILE
- 4.4.7 COLOMBIA
- 4.4.8 ECUADOR
- 4.4.9 EL SALVADOR
- 4.4.10 GUATEMALA
- 4.4.11 GUYANA
- 4.4.12 HONDURAS
- 4.4.13 MEXICO
- 4.4.14 NICARAGUA
- 4.4.15 PANAMA
- 4.4.16 PARAGUAY
- 4.4.17 PERU
- 4.4.18 SURINAME
- 4.4.19 URUGUAY
- 4.5 NORTH AMERICA & THE CARIBBEAN: GLYCOSIDES, GLANDS OR OTHER ORGANS AND EXTRACTS, ANTISERA, VACCINES, AND SIMILAR PRODUCTS IMPORTS IN 2024
- 4.5.1 EXECUTIVE SUMMARY
- 4.5.2 ANTIGUA AND BARBUDA
- 4.5.3 ARUBA
- 4.5.4 BARBADOS
- 4.5.5 BERMUDA
- 4.5.6 CANADA
- 4.5.7 GREENLAND
- 4.5.8 JAMAICA
- 4.5.9 THE BAHAMAS
- 4.5.10 THE DOMINICAN REPUBLIC
- 4.5.11 THE UNITED STATES
- 4.6 OCEANIA: GLYCOSIDES, GLANDS OR OTHER ORGANS AND EXTRACTS, ANTISERA, VACCINES, AND SIMILAR PRODUCTS IMPORTS IN 2024
- 4.6.1 EXECUTIVE SUMMARY
- 4.6.2 AUSTRALIA
- 4.6.3 FIJI
- 4.6.4 FRENCH POLYNESIA
- 4.6.5 NEW CALEDONIA
- 4.6.6 NEW ZEALAND
- 4.6.7 PALAU
- 4.6.8 TONGA
- 4.7 THE MIDDLE EAST: GLYCOSIDES, GLANDS OR OTHER ORGANS AND EXTRACTS, ANTISERA, VACCINES, AND SIMILAR PRODUCTS IMPORTS IN 2024
- 4.7.1 EXECUTIVE SUMMARY
- 4.7.2 ARMENIA
- 4.7.3 AZERBAIJAN
- 4.7.4 BAHRAIN
- 4.7.5 ISRAEL
- 4.7.6 JORDAN
- 4.7.7 KUWAIT
- 4.7.8 LEBANON
- 4.7.9 OMAN
- 4.7.10 PAKISTAN
- 4.7.11 QATAR
- 4.7.12 TURKEY
- 4.7.13 YEMEN
- 5 DISCLAIMERS, WARRANTIES, AND USER AGREEMENT PROVISIONS
- 5.1 DISCLAIMERS & SAFE HARBOR
- 5.2 ICON GROUP INTERNATIONAL, INC. USER AGREEMENT PROVISIONS
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook